focus -WSS

focus

author：comprehensive 2025-09-28 23:49:20 - browse：41

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： A letter from the executive editor: The 2023 STATUS List

focus

WSS

Scientists unlock the key to scar

The biotech scorecard for Q3: 15 stock

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Undocumented workers face uncertainty as immigration law takes effect in Florida

STAT wants to know your pick for a great summer read or listen

hotspot

focus

leisure time

How to save PrEP access — and even expand it

Hubble vs. James Webb telescope images: See the difference

State Dept. review finds Biden bears some blame for Afghanistan failures

Prescription digital therapeutics are key to pharma’s future

The cancer drug shortage isn’t new — and neither are the solutions

Biotech companies concerned about China biosecurity crackdown

23andMe had bad news about my health. I wish a person had delivered it

Canadians with cystic fibrosis outlive Americans by a decade

Novavax promises a turnaround & Lilly roils the obesity market

UpToDate has a racism problem: Dr. Stanley Goldfarb

leisure time

'Screen and refer' systems are hurting patients

Beware reading your test results before your doctor does

RSV vaccines may be linked to small increased risk of developing GBS

How Robert F. Kennedy Jr. distorted vaccine science

FogPharma raises $145 million in rare Series E round

Change Healthcare cyberattack outage could last weeks

focus

focus

explore

hotspot